Open Pharma is proud to announce that Eli Lilly and Company has joined Open Pharma as a Member.
Open Pharma aims to drive positive change in the communication of research funded by the pharmaceutical industry, with a focus on improving the transparency, accountability, accessibility and discoverability of published research.
Lilly is an American medicine company turning science into healing to make life better for people around the world.
By joining Open Pharma as a Member, Lilly is demonstrating its commitment to expanding equitable access by leading innovation in healthcare communications. This vision is shared by all Members and Supporters of Open Pharma, who aim to make the highest quality, peer-reviewed evidence available and accessible to anyone who needs it, anywhere in the world.
As Joana Osório, Communications Team Leader at Oxford PharmaGenesis and Project Lead at Open Pharma, explains, “cross-industry collaboration is essential to shape the future of pharma research communications. We’re delighted to welcome a company with such a strong focus on innovation as a new voice in Open Pharma.”
Lilly joins 17 existing Members and Supporters of Open Pharma from across the publishing, medical communications and pharmaceutical industries (AstraZeneca, Boehringer Ingelheim, Galápagos, Gilead, GSK, Janssen/Johnson & Johnson, Novartis, Novo Nordisk, Oxford PharmaGenesis, Pfizer, Takeda, UCB, Astellas, Bristol Myers Squibb, Ipsen, Roche and Taylor & Francis).
About Open Pharma
Open Pharma, a multi-sponsor collaboration facilitated by Oxford PharmaGenesis, is driving positive change in the communication of pharma-sponsored research. Open Pharma is working to improve the pharma publications model by connecting pharma with innovations in publishing to increase transparency and access to research outputs. Our four core goals are:
- Transparency – aiming to increase access to scientific information to advance medical science and improve patient care
- Accountability – aiming to increase accountability and transparency and reduce administrative burden
- Accessibility – aiming for faster and wider dissemination of results, increased citations and use of results
- Discoverability – aiming to have targeted content for each user group available from a single point
For more information contact: OxfordProject@pharmagenesis.com
Related information
Open Pharma
Online: https://www.openpharma.blog/
LinkedIn: www.linkedin.com/showcase/open-pharma
Twitter/X: www.twitter.com/_openpharma
YouTube: www.youtube.com/@openpharma6043
Figshare: openpharma.figshare.com
